Reports
Reports
Sale
The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:
Key Trends | Impact |
Increased Focus on Combination Therapies | There is a growing interest in combination therapies that target multiple pathways to induce weight loss. Such combinations can offer better efficacy as compared to conventional monotherapies. |
Heightened Patient Awareness | There is an increased awareness and acceptance of obesity as a chronic disease requiring medical intervention, rather than just lifestyle changes. This shift is contributing to the rising anti-obesity drugs market demand. |
Regulatory Support | Regulatory agencies are providing transparent guidelines and support for the development and approval of anti-obesity drugs. This includes fast-track designations and approvals for drugs that exhibit significant benefits in clinical trials. |
Increased Use of GLP-1 Receptor Agonists | Glucagon-like peptide-1 (GLP-1) receptor agonists, originally developed for diabetes treatment, are increasingly preferred for obesity management due to their ability to induce weight loss. |
Anti-Obesity Drugs Market Size
Anti-Obesity Drugs Market Growth
Anti-Obesity Drugs Market Trends
Anti-Obesity Drugs Market Share
Anti-Obesity Drugs Market Regional Analysis
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Anti-Obesity Drugs Market Overview – 8 Major Markets
3.1 Anti-Obesity Drugs Market Historical Value (2017-2023)
3.2 Anti-Obesity Drugs Market Forecast Value (2024-2032)
4 Obesity Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Anti-Obesity Drugs Epidemiology Scenario and Forecast – 8 Major Markets
6.1 8MM Epidemiology Scenario Overview (2017-2032)
6.2 United States Obesity Epidemiology Scenario and Forecast (2017-2032)
6.3 EU-4 and United Kingdom Obesity Epidemiology Scenario and Forecast (2017-2032)
6.3.1 Germany Obesity Epidemiology Scenario and Forecast (2017-2032)
6.3.2 France Obesity Epidemiology Scenario and Forecast (2017-2032)
6.3.3 Italy Obesity Epidemiology Scenario and Forecast (2017-2032)
6.3.4 Spain Obesity Epidemiology Scenario and Forecast (2017-2032)
6.3.5 United Kingdom Obesity Epidemiology Scenario and Forecast (2017-2032)
6.4 Japan Obesity Epidemiology Scenario and Forecast (2017-2032)
6.5 India Obesity Epidemiology Scenario and Forecast (2017-2032)
7 Anti-Obesity Drugs Market Landscape – 8 Major Markets
7.1 Anti-Obesity Drugs: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Anti-Obesity Drugs: Product Landscape
7.2.1 Analysis by Prescription Type
7.2.2 Analysis by Drug Type
7.2.3 Analysis by Drug Class
7.2.4 Analysis by Mechanism of Action
7.2.5 Analysis by Route of Administration
8 Anti-Obesity Drugs Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Anti-Obesity Drugs Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Anti-Obesity Drugs Market Segmentation (2017-2032) - 8 Major Markets
11.1 Anti-Obesity Drugs Market (2017-2032) by Drug Type
11.1.1 Market Overview
11.1.2 Semaglutide
11.1.3 Phentermine/Topiramate
11.1.4 Naltrexone/Bupropion
11.1.5 Liraglutide
11.1.6 Gelesis 100
11.1.7 Orlistat
11.1.8 Phentermine
11.1.9 Methamphetamine
11.1.10 Tirzepatide
11.1.11 Others
11.2 Anti-Obesity Drugs Market (2017-2032) by Drug Class
11.2.1 Market Overview
11.2.2 Amphetamine
11.2.3 GLP-1 Receptor Agonist
11.2.4 Lipase Inhibitor
11.2.5 Others
11.3 Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
11.3.1 Market Overview
11.3.2 Centrally Acting Drugs
11.3.3 Peripherally Acting Drugs
11.4 Anti-Obesity Drugs Market (2017-2032) by Prescription Type
11.4.1 Market Overview
11.4.2 Prescription Drugs
11.4.3 Over The Counter Drugs
11.5 Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
11.5.1 Market Overview
11.5.2 Hospital Pharmacies
11.5.3 Drug Store & Retail Pharmacies
11.5.4 Online Pharmacies
11.6 Anti-Obesity Drugs Market (2017-2032) by Region
11.6.1 Market Overview
11.6.2 United States
11.6.3 EU-4 and the United Kingdom
11.6.3.1 Germany
11.6.3.2 France
11.6.3.3 Italy
11.6.3.4 Spain
11.6.3.5 United Kingdom
11.6.4 Japan
11.6.5 India
12 United States Anti-Obesity Drugs Market (2017-2032)
12.1 United States Anti-Obesity Drugs Market Historical Value (2017-2023)
12.2 United States Anti-Obesity Drugs Market Forecast Value (2024-2032)
12.3 United States Anti-Obesity Drugs Market (2017-2032) by Drug Type
12.3.1 Market Overview
12.3.2 Semaglutide
12.3.3 Phentermine/topiramate
12.3.4 Naltrexone/bupropion
12.3.5 Liraglutide
12.3.6 Gelesis 100
12.3.7 Orlistat
12.3.8 Phentermine
12.3.9 Methamphetamine
12.3.10 Tirzepatide
12.4 United States Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
12.4.1 Market Overview
12.4.2 Centrally Acting Drugs
12.4.3 Peripherally Acting Drugs
13 EU-4 and United Kingdom Anti-Obesity Drugs Market (2017-2032)
13.1 EU-4 and United Kingdom Anti-Obesity Drugs Market Historical Value (2017-2023)
13.2 EU-4 and United Kingdom Anti-Obesity Drugs Market Forecast Value (2024-2032)
13.3 EU-4 and United Kingdom Anti-Obesity Drugs Market Overview
13.4 EU-4 and United Kingdom Anti-Obesity Drugs Market (2017-2032) by Drug Type
13.4.1 Market Overview
13.4.2 Semaglutide
13.4.3 Phentermine/topiramate
13.4.4 Naltrexone/bupropion
13.4.5 Liraglutide
13.4.6 Gelesis 100
13.4.7 Orlistat
13.4.8 Phentermine
13.4.9 Methamphetamine
13.4.10 Tirzepatide
13.5 EU-4 and United Kingdom Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
13.5.1 Market Overview
13.5.2 Centrally Acting Drugs
13.5.3 Peripherally Acting Drugs
14 Japan Anti-Obesity Drugs Market
14.1 Japan Anti-Obesity Drugs Market Historical Value (2017-2023)
14.2 Japan Anti-Obesity Drugs Market Forecast Value (2024-2032)
14.3 Japan Anti-Obesity Drugs Market (2017-2032) by Drug Type
14.3.1 Market Overview
14.3.2 Semaglutide
14.3.3 Phentermine/topiramate
14.3.4 Naltrexone/bupropion
14.3.5 Liraglutide
14.3.6 Gelesis 100
14.3.7 Orlistat
14.3.8 Phentermine
14.3.9 Methamphetamine
14.3.10 Tirzepatide
14.4 Japan Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
14.4.1 Market Overview
14.4.2 Centrally Acting Drugs
14.4.3 Peripherally Acting Drugs
15 India Anti- Obesity Drugs Market
15.1 India Anti-Obesity Drugs Market (2017-2032) Historical Value (2017-2023)
15.2 India Anti-Obesity Drugs Market (2017-2032) Forecast Value (2024-2032)
15.3 India Anti-Obesity Drugs Market (2017-2032) by Drug Type
15.3.1 Market Overview
15.3.2 Semaglutide
15.3.3 Phentermine/topiramate
15.3.4 Naltrexone/bupropion
15.3.5 Liraglutide
15.3.6 Gelesis 100
15.3.7 Orlistat
15.3.8 Phentermine
15.3.9 Methamphetamine
15.3.10 Tirzepatide
15.4 India Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
15.4.1 Market Overview
15.4.2 Centrally Acting Drugs
15.4.3 Peripherally Acting Drugs
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 Japan PMDA
16.1.4 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication Year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by Year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 GlaxoSmithKline PLC
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisitions
22.1.5 Certifications
22.2 Pfizer Inc.
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisitions
22.2.5 Certifications
22.3 Novo Nordisk A/S
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisitions
22.3.5 Certifications
22.4 Rhythm Pharmaceuticals
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisitions
22.4.5 Certifications
22.5 KVK Tech Inc.
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisitions
22.5.5 Certifications
22.6 Currax Pharmaceuticals LLC
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisitions
22.6.5 Certifications
22.7 CHEPLAPHARM Arzneimittel GmbH
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisitions
22.7.5 Certifications
22.8 Vivus LLC
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisitions
22.8.5 Certifications
22.9 Gelesis Holding Inc.
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisitions
22.9.5 Certifications
22.10 Boehringer Ingelheim International GmbH
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisitions
22.10.5 Certifications
22.11 Eli Lilly and Company
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisitions
22.11.5 Certifications
List not exhaustive
23 Anti-Obesity Drugs Treatment Drugs - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Datasheet
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.